Molecular genetics of clear-cell renal cell carcinoma

Journal of Clinical Oncology

Volumn 32, Issue 18, 2014, Pages 1968-1976

  Brugarolas, James ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; ELONGIN C; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3CA PROTEIN; POLYBROMO 1 PROTEIN; PROTEIN; SET DOMAIN CONTAINING PROTEIN 2; TUBEROUS SCLEROSIS 1 PROTEIN; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; ANTINEOPLASTIC AGENT; BAP1 PROTEIN, HUMAN; HISTONE LYSINE METHYLTRANSFERASE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; NUCLEAR PROTEIN; PBRM1 PROTEIN, HUMAN; SET2 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TRANSCRIPTION FACTOR; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN THIOLESTERASE; VHL PROTEIN, HUMAN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GENETICS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; CHROMOSOME 3P; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; HUMAN; IN VITRO STUDY; KIDNEY CARCINOMA; MASSIVELY PARALLEL SEQUENCING; MOLECULAR GENETICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; KIDNEY TUMOR; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; MULTIPROTEIN COMPLEXES; MUTATION; NUCLEAR PROTEINS; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84905403670     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.2003     Document Type: Article

References (89)

1. Ferlay J, Shin HR, Bray F, et al: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917, 2010
2. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63:11-30, 2013
3. Howlader N, Noone AM, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2010. Bethesda, MD, National Cancer Institute, 2013
4. Baldewijns MM, van Vlodrop IJ, Schouten LJ, et al: Genetics and epigenetics of renal cell cancer. Biochim Biochim Biophys Acta 1785:133-155, 2008
5. Creighton CJ, Morgan M, Gunaratne PH, et al: Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499:43-49, 2013
6. Sato Y, Yoshizato T, Shiraishi Y, et al: Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 45:860-867, 2013
7. Gerlinger M, Rowan AJ, Horswell S, et al: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883-892, 2012
8. Vogelstein B, Papadopoulos N, Velculescu VE, et al: Cancer genome landscapes. Science 339: 1546-1558, 2013
9. Tomasetti C, Vogelstein B, Parmigiani G: Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. Proc Natl Acad Sci U S A 110:1999-2004, 2013
10. Greaves M, Maley CC: Clonal evolution in cancer. Nature 481:306-313, 2012
11. Peña-Llopis S, Christie A, Xie XJ, et al: Cooperation and antagonism among cancer genes: The renal cancer paradigm. Cancer Res 73:4173-4179, 2013
12. Peña-Llopis S, Vega-Rubín-de-Celis S, Liao A, et al: BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 44:751-759, 2012
13. Heyn H, Esteller M: DNA methylation profiling in the clinic: Applications and challenges. Nat Rev Genet 13:679-692, 2012
14. Gnarra JR, Tory K, Weng Y, et al: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7:85-90, 1994 (Pubitemid 24232386)
15. Herman JG, Latif F, Weng Y, et al: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 91:9700-9704, 1994 (Pubitemid 24311875)
16. Nickerson ML, Jaeger E, Shi Y, et al: Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 14:4726-4734, 2008
17. Latif F, Tory K, Gnarra J, et al: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317-1320, 1993 (Pubitemid 23231974)
18. Zbar B, Brauch H, Talmadge C, et al: Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature 327:721-724, 1987 (Pubitemid 17085908)
19. Beroukhim R, Brunet JP, Di Napoli A, et al: Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 69:4674-4681, 2009
20. Chen M, Ye Y, Yang H, et al: Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. Int J Cancer 125:2342-2348, 2009
21. Shen C, Kaelin WG Jr: The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol 23:18-25, 2013
22. Stebbins CE, Kaelin WG Jr, Pavletich NP: Structure of the VHL-ElonginC-ElonginB complex: Implications for VHL tumor suppressor function. Science 284:455-461, 1999 (Pubitemid 29289612)
23. Varela I, Tarpey P, Raine K, et al: Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469:539-542, 2011
24. Dawson MA, Kouzarides T, Huntly BJ: Targeting epigenetic readers in cancer. N Engl J Med 367:647-657, 2012
25. Clapier CR, Cairns BR: The biology of chromatin remodeling complexes. Annu Rev Biochem 78:273-304, 2009
26. Wilson BG, Roberts CW: SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 11:481-492, 2011
27. Reisman D, Glaros S, Thompson EA: The SWI/SNF complex and cancer. Oncogene 28:1653-1668, 2009
28. Kadoch C, Hargreaves DC, Hodges C, et al: Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet 45:592-601, 2013
29. Thompson M: Polybromo-1: The chromatin targeting subunit of the PBAF complex. Biochimie 91:309-319, 2009
30. Kapur P, Peña-Llopis S, Christie A, et al: Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: A retrospective analysis with independent validation. Lancet Oncol 14:159-167, 2013
31. Brownlee PM, Chambers AL, Oliver AW, et al: Cancer and the bromodomains of BAF180. Biochem Soc Trans 40:364-369, 2012
32. Wellcome Trust Sanger Institute: Catalog of Somatic Mutations in Cancer. http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/
33. Xia W, Nagase S, Montia AG, et al: BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer. Cancer Res 68:1667-1674, 2008 (Pubitemid 351416550)
34. Burrows AE, Smogorzewska A, Elledge SJ: Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence. Proc Natl Acad Sci U S A 107:14280-14285, 2010
35. Brugarolas J: PBRM1 and BAP1 as novel targets for renal cell carcinoma. Cancer J 19:324-332, 2013
36. Dalgliesh GL, Furge K, Greenman C, et al: Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463:360-363, 2010
37. Hakimi AA, Ostrovnaya I, Reva B, et al: Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: A report by MSKCC and the KIRC TCGA research network. Clin Cancer Res 19:3259-3267, 2013
38. Edmunds JW, Mahadevan LC, Clayton AL: Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation. EMBO J 27:406-420, 2008 (Pubitemid 351161656)
39. Wagner EJ, Carpenter PB: Understanding the language of Lys36 methylation at histone H3. Nat Rev Mol Cell Biol 13:115-126, 2012
40. Li F, Mao G, Tong D, et al: The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSα. Cell 153:590-600, 2013
41. Alexandrov LB, Nik-Zainal S, Wedge DC, et al: Signatures of mutational processes in human cancer. Nature 500:415-421, 2013
42. Guo G, Gui Y, Gao S, et al: Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet 44:17-19, 2012
43. Jensen DE, Proctor M, Marquis ST, et al: BAP1: A novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 16:1097-1112, 1998 (Pubitemid 28127509)
44. Kucejova B, Peña-Llopis S, Yamasaki T, et al: Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma. Mol Cancer Res 9:1255-1265, 2011
45. Machida YJ, Machida Y, Vashisht AA, et al: The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. J Biol Chem 284:34179-34188, 2009
46. Yu H, Mashtalir N, Daou S, et al: The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression. Mol Cell Biol 30:5071-5085, 2010
47. Sowa ME, Bennett EJ, Gygi SP, et al: Defining the human deubiquitinating enzyme interaction landscape. Cell 138:389-403, 2009
48. Joseph RW, Kapur P, Serie DJ, et al: Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low risk clear cell renal cell carcinoma. Cancer doi: 10.1002/cncr.28521 [epub ahead of print on December 30, 2013]
49. Harbour JW, Onken MD, Roberson ED, et al: Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330:1410-1413, 2010
50. Bott M, Brevet M, Taylor BS, et al: The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 43:668-672, 2011
51. Testa JR, Cheung M, Pei J, et al: Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43:1022-1025, 2011
52. Wiesner T, Obenauf AC, Murali R, et al: Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 43:1018-1021, 2011
53. Popova T, Hebert L, Jacquemin V, et al: Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet 92:974-980, 2013
54. Farley MN, Schmidt LS, Mester JL, et al: A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma. Mol Cancer Res 11:1061-1071, 2013
55. Ventii KH, Devi NS, Friedrich KL, et al: BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res 68:6953-6962, 2008
56. Misaghi S, Ottosen S, Izrael-Tomasevic A, et al: Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1. Mol Cell Biol 29:2181-2192, 2009
57. Scheuermann JC, de Ayala Alonso AG, Oktaba K, et al: Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 465:243-247, 2010
58. Sauvageau M, Sauvageau G: Polycomb group proteins: Multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 7:299-313, 2010
59. Mills AA: Throwing the cancer switch: Reciprocal roles of polycomb and trithorax proteins. Nat Rev Cancer 10:669-682, 2010
60. Dey A, Seshasayee D, Noubade R, et al: Loss of the tumor suppressor BAP1 causes myeloid transformation. Science 337:1541-1546, 2012
61. Eletr ZM, Wilkinson KD: An emerging model for BAP1's role in regulating cell cycle progression. Cell Biochem Biophys 60:3-11, 2011
62. Kristie TM, Liang Y, Vogel JL: Control of alpha-herpesvirus IE gene expression by HCF-1 coupled chromatin modification activities. Biochim Biochim Biophys Acta 1799:257-265, 2010
63. Gossage L, Murtaza M, Slatter AF, et al: Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. Genes Chromosomes Cancer 53:38-51, 2014
64. Kapur P, Christie A, Raman JD, et al: BAP1 immunohistochemistry predicts outcomes in a multi-institutional cohort with clear cell renal cell carcinoma. J Urol 191:603-610, 2014
65. Harbour JW: The genetics of uveal melanoma: An emerging framework for targeted therapy. Pigment Cell Melanoma Res 25:171-181, 2012
66. Mandriota SJ, Turner KJ, Davies DR, et al: HIF activation identifies early lesions in VHL kidneys: Evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1:459-468, 2002 (Pubitemid 41039126)
67. Montani M, Heinimann K, von Teichman A, et al: VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: Further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease. Am J Surg Pathol 34:806-815, 2010
68. Ho L, Ronan JL, Wu J, et al: An embryonic stem cell chromatin remodeling complex, esBAF, is essential for embryonic stem cell self-renewal and pluripotency. Proc Natl Acad Sci U S A 106:5181-5186, 2009
69. Sohn DH, Lee KY, Lee C, et al: SRG3 interacts directly with the major components of the SWI/SNF chromatin remodeling complex and protects them from proteasomal degradation. J Biol Chem 282:10614-10624, 2007 (Pubitemid 47093407)
70. Kim JK, Huh SO, Choi H, et al: Srg3, a mouse homolog of yeast SWI3, is essential for early embryogenesis and involved in brain development. Mol Cell Biol 21:7787-7795, 2001 (Pubitemid 32988787)
71. Sellers WR: A blueprint for advancing genetics-based cancer therapy. Cell 147:26-31, 2011
72. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, et al: The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 11:329-341, 2010
73. Kondo K, Yao M, Kobayashi K, et al: PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines. Int J Cancer 91:219-224, 2001 (Pubitemid 32041743)
74. Dibble CC, Manning BD: Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol 15:555-564, 2013
75. Benvenuto G, Li S, Brown SJ, et al: The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene 19:6306-6316, 2000 (Pubitemid 32641844)
76. Kucejova B, Sunny NE, Nguyen AD, et al: Uncoupling hypoxia signaling from oxygen sensing in the liver results in hypoketotic hypoglycemic death. Oncogene 30:2147-2160, 2011
77. Mazhab-Jafari MT, Marshall CB, Ishiyama N, et al: An autoinhibited noncanonical mechanism of GTP hydrolysis by Rheb maintains mTORC1 homeostasis. Structure 20:1528-1539, 2012
78. Zoncu R, Efeyan A, Sabatini DM: mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12:21-35, 2011
79. Fingar DC, Blenis J: Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23:3151-3171, 2004 (Pubitemid 38638827)
80. Yang H, Rudge DG, Koos JD, et al: mTOR kinase structure, mechanism and regulation. Nature 497:217-223, 2013
81. Sato T, Nakashima A, Guo L, et al: Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene 29:2746-2752, 2010
82. Voss MH, Hakimi AA, Chen Y, et al: Effective monotherapy despite intratumor heterogeneity: Clonal convergence within the PI3K pathway and sensitivity to mTOR inhibitors in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 31:302s 2013, (suppl; abstr 4573)
83. Brugarolas J: Research translation and personalized medicine, in Figlin RA, Rathmell WK, Rini BI (eds): Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets. New York, NY, Springer US, 2012, pp 161-191
84. Iyer G, Hanrahan AJ, Milowsky MI, et al: Genome sequencing identifies a basis for everolimus sensitivity. Science 338:221, 2012
85. Tinton SA, Buc-Calderon PM: Hypoxia increases the association of 4E-binding protein 1 with the initiation factor 4E in isolated rat hepatocytes. FEBS Lett 446:55-59, 1999 (Pubitemid 29127249)
86. Brugarolas J: MTORC1 signaling and hypoxia, in Polunovsky VAA, Houghton PJJ (eds): mTOR Pathway and mTOR Inhibitors in Cancer Therapy. Cancer Drug Discovery and Development, Humana Press, 2010, pp 75-97
87. Wolff NC, Vega-Rubin-de-Celis S, Xie XJ, et al: Cell-type-dependent regulation of mTORC1 by REDD1 and the tumor suppressors TSC1/TSC2 and LKB1 in response to hypoxia. Mol Cell Biol 31:1870-1884, 2011
88. Brugarolas J, Lei K, Hurley RL, et al: Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 18:2893-2904, 2004 (Pubitemid 39602308)
89. Pantuck AJ, Seligson DB, Klatte T, et al: Prognostic relevance of the mTOR pathway in renal cell carcinoma: Implications for molecular patient selection for targeted therapy. Cancer 109:2257-2267, 2007 (Pubitemid 46801555)